Clinical trial NCT03820817: Rifaximin in Patients With Monoclonal Gammopathy
Official title: Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: IgA Monoclonal Gammopathy
IgG Monoclonal Gammopathy
IgM Monoclonal Gammopathy
Light Chain Deposition Disease
Monoclonal Gammopathy
Smoldering Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia
Gammopathy, Monoclonal
Gammopathy Igg
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2019-01-29
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Detailed description: PRIMARY OBJECTIVE:

I. To evaluate the effect of a 2-week course of rifaximin on clonal immunoglobulin (Ig) in patients with monoclonal gammopathy.

SECONDARY OBJECTIVES:

I. To evaluate safety and tolerability of a 2-week course of rifaximin.

II. To evaluate changes in stool microbiota by 16S ribosomal ribonucleic acid (rRNA) gene (16S) sequencing.

III. To evaluate changes in gammopathy as assessed by changes in clonal Ig and/or plasma cells.

OUTLINE:

Patients receive rifaximin orally (PO) thrice daily (TID) on days 1-14 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 8 weeks.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of monoclonal gammopathy of undetermined significance based on International Myeloma Working Group (IMWG) criteria
* Patients will be enrolled into one of 3 cohorts:

  * Cohort A: IgA gammopathy
  * Cohort B: IgG gammopathy / or light chain gammopathy
  * Cohort C: IgM gammopathy / asymptomatic macroglobulinemia
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Patients who have received antibiotics within last 3 weeks
* Patients who are receiving any other investigational agents for gammopathy. Patients with clinical myeloma requiring anti-myeloma therapy are also excluded
* History of allergic reactions or intolerance attributed to rifaximin or compounds of similar chemical or biologic composition to antibiotic under study
* The effects of rifaximin on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of rifaximin administration

Primary outcomes:
measure: Clinical response rate defined as a reduction in clonal immunoglobulin (Ig) by > 25%
timeFrame: Up to 2 weeks after study start
Secondary outcomes:
measure: Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
timeFrame: Up to 12 weeks after study start
measure: Changes in stool microbiota
timeFrame: Up to 12 weeks after study start
measure: Changes in gammopathy
timeFrame: Up to 12 weeks after study start
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Emory University Hospital/Winship Cancer Institute
state: Georgia
Study officials:
affiliation: Emory University
name: Ajay Nooka, MD
role: PRINCIPAL_INVESTIGATOR
References: